HOME >> BIOLOGY >> NEWS
New medications, cancer diagnosis goals of UH engineers with $1M in grants

HOUSTON, Feb. 8, 2007 Identifying new medications and providing foolproof cancer diagnosis are two benefits anticipated from research by a team of engineering professors at the University of Houston.

A tabletop system capable of screening tens of thousands of drug candidates in an hour and a tool that can provide a reliable cancer diagnosis with minuscule quantities of tissue obtained through non-invasive means are just two possible outcomes of research led by Dmitri Litvinov, associate professor of electrical and computer engineering and of chemical and biomolecular engineering in the Cullen College of Engineering at UH. Along with his co-investigators Richard Willson, professor of chemical engineering and biochemical and biophysical sciences, and John Wolfe, professor of electrical and computer engineering, Litvinov and his team received more than $1 million in grants from the National Institutes of Health and the Alliance for NanoHealth.

Together, they are developing versatile technology that will enable such breakthroughs as rapid evaluation of the effectiveness of potential antiviral drugs by their ability to block a virus bond with a cell receptor, as well as high-precision detection of cancer biomarkers using molecular binding as a means for biorecognition. While it is common to utilize these natural molecular binding processes to identify biological agents, Litvinovs research distinguishes itself by how these processes are detected.

Usually scientists attach tags, also referred to as labels, to biomolecules (proteins, DNAs or RNAs) that allow these biomolecules to be tracked. This tracking tells researchers the location of the biomolecules and whether the biomolecules have bonded with a specific substrate, such as a healthy cell.

Common tags used by researchers are fluorescent beads that are detectable by their coloring, but many of the tags currently used in research are much larger than the biomolecule
'"/>

Contact: Lisa Merkl
lkmerkl@uh.edu
713-743-8192
University of Houston
8-Feb-2007


Page: 1 2 3 4

Related biology news :

1. Protein chatter linked to cancer activation
2. Newly created cancer stem cells could aid breast cancer research
3. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless
4. ESF EURYI award winner aims to stop cancer cells reading their own DNA
5. No evidence that widely prescribed statins protect against prostate cancer
6. A study by the MUHC and McGill University opens a new door to understanding cancer
7. New study suggests Concord grape juice may provide protection against breast cancer
8. New test improves detection of liver cancer
9. High-intensity ultrasound may launch attack on cancer, wherever it lurks
10. Unknotting DNA clue to cancer syndrome
11. Biologists at Tufts University discover 1 reason why chromosomes break, often leading to cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... WEST LAFAYETTE, Indiana (PRWEB) , ... ... ... a division of Albany Molecular Research Inc. has further extended its industry ... sector. This service offers state-of-the-art cGMP techniques and methods for the ...
(Date:2/15/2017)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial ... full year ended December 31, 2016. ... we continued to demonstrate strong growth in our ... said Mihael H. Polymeropoulos, M.D., Vanda,s President and ... 2017 milestones underscores Vanda,s commitment to bringing important ...
Breaking Biology Technology:
Cached News: